Showing results (11-20 of 34) with videos related to

Sort By:
Pageof 4
Clinical Colorectal Cancer|August 25, 2021
Long Term Survival With Regorafenib: REALITY (Real Life in Italy) Trial - A GISCAD StudyEleonora Lai, Marco Puzzoni, Pina Ziranu, et al.
British Journal of Cancer|February 9, 2023
Trop-2 and Nectin-4 immunohistochemical expression in metastatic colorectal cancer: searching for the right population for drugs' developmentRoberto Moretto, Marco Maria Germani, Mirella Giordano, et al.
European Journal of Cancer (Oxford, England : 1990)|June 14, 2021
Exploring clinical and gene expression markers of benefit from FOLFOXIRI/bevacizumab in patients with BRAF-mutated metastatic colorectal cancer: Subgroup analyses of the TRIBE2 studyRoberto Moretto, Mirella Giordano, Anello M Poma, et al.
Cancer Treatment Reviews|January 11, 2022
Bevacizumab-induced hypertension as a predictor of clinical outcome in metastatic colorectal cancer: An individual patient data-based pooled analysis of two randomized studies and a systematic review of the literaturePasquale Lombardi, Daniele Rossini, Veronica Crespi, et al.
Journal for Immunotherapy of Cancer|April 21, 2023
Dissecting tumor lymphocyte infiltration to predict benefit from immune-checkpoint inhibitors in metastatic colorectal cancer: lessons from the AtezoT RIBE studyRoberto Moretto, Daniele Rossini, Aurélie Catteau, et al.
European Journal of Cancer (Oxford, England : 1990)|April 30, 2025
The relative dose intensity of first-line FOLFOXIRI and FOLFOX/FOLFIRI both in combination with bevacizumab affects prognosis of metastatic colorectal cancer patients: A pooled analysis of TRIBE and TRIBE2 studiesR Moretto, D Rossini, Mariam Grazia Polito, et al.
JCO Precision Oncology|April 18, 2025
Exploring the Prognostic and Predictive Impact of Genomic Loss of Heterozygosity and Homologous Recombination Deficiency Alterations in Patients With Metastatic Colorectal CancerRoberto Moretto, Marco Maria Germani, Martina Carullo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 23, 2023
Negative Hyperselection of Patients with HER2+ and RAS Wild-Type Metastatic Colorectal Cancer Receiving Dual HER2 Blockade: the PRESSING-HER2 StudyGiovanni Randon, Yoshiaki Nakamura, Rona Yaeger, et al.
Frontiers in Oncology|February 26, 2024
Molecular screening with liquid biopsy for anti-EGFR retreatment in metastatic colorectal cancer: preliminary data from the randomized phase 2 PARERE trialMarco Maria Germani, Guglielmo Vetere, Mirella Giordano, et al.
European Journal of Cancer (Oxford, England : 1990)|March 1, 2022
Early modulation of Angiopoietin-2 plasma levels predicts benefit from regorafenib in patients with metastatic colorectal cancerCarlotta Antoniotti, Federica Marmorino, Alessandra Boccaccino, et al.
Pageof 4